Clover Health Investments (CLOV) Earnings Dates, Call Summary & Reports

3,594 Followers

Earnings Data

Report Date

Aug 10, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

0.04

Last Year’s EPS

-0.02

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 06, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a strong set of operational and financial positives: rapid membership growth (~51% YoY), significant revenue growth (+62% YoY), improved gross profit (+47% YoY), GAAP profitability ($27M) and expanding clinical engagement (Clover Assistant reach and Clover Care enrollment up ~90%). Management acknowledged elevated outpatient utilization, Part D and prior-period reserve variability and one-time SG&A items, but described concrete actions (AI/data, dental cost controls, targeted remediation) and emphasized disciplined monitoring. Given the magnitude and breadth of the favorable metrics and the balance of challenges being described as manageable or being actively addressed, the overall tone is optimistic and confidence-driven while cautious on cohort maturation risks.

Company Guidance

Clover reiterated it expects to meet or exceed its full‑year 2026 outlook across all metrics (and to deliver full‑year GAAP net income profitability), but will revisit guidance after Q2; Q1 results underpinning that view included ~156,000 MA members (over +52k YoY / ~51% growth), $749M revenue (+62% YoY), $160M consolidated gross profit (+47% YoY), insurance BER of 86.5%, GAAP net income of $27M (up $29M YoY), adjusted EBITDA of $40M (+56% YoY), adjusted SG&A of $119M (16% of revenue, ~200 bps YoY improvement versus a 100–150 bps target), $418M cash and investments with no debt, $108M operating cash flow, >1/3 of members receiving Clover Assistant care, Clover Care enrollment +~90% YoY, and noted inpatient utilization drove ~25–30 bps of margin favorability while they continue to monitor outpatient and Part D trends.

Strong Membership Growth

Medicare Advantage membership grew ~51% year-over-year to approximately 156,000 members (an increase of over 52,000 lives), driven by a strong AEP and best-in-class retention.

Revenue and Profitability Expansion

Total revenues were $749 million, up 62% year-over-year. The company generated GAAP net income of $27 million (improving by $29 million YoY) and adjusted EBITDA of $40 million, up 56% YoY.

Improving Gross Profit and Cohort Economics

Consolidated gross profit was $160 million, up 47% year-over-year. Management emphasized improving cohort economics as new members mature under Clover's care model.

Operational and Clinical Engagement Momentum

Over one-third of members received Clover Assistant-powered care in Q1, and enrollment in Clover Care Services (home care) rose ~90% year-over-year, supporting higher-acuity management and better outcomes.

SG&A Efficiency Gains and Scale Benefits

Adjusted SG&A was $119 million (16% of revenue), improving roughly 200 basis points year-over-year due to scale, vendor optimization and early impact from automation/AI-driven workflows; company remains committed to 100–150 bps improvement for 2026 and delivered 200 bps in Q1.

Strong Balance Sheet and Cash Generation

Ended the quarter with $418 million in cash and investments, no debt, and operating cash flow of $108 million in the quarter, supporting self-funded growth.

Data/AI and Regulatory Positioning

Expanded capabilities onto new CMS-aligned networks to access earlier data for AI-driven insights; CMS did not finalize proposed risk model changes (creating stability) and adopted a switcher exception that management says benefits plans like Clover that rely on encounter-linked documentation.

Market Leadership in Core Geography

Clover is now the largest PPO in New Jersey (excluding special needs and employer retiree plans), enabling concentrated clinical integration and reinforcing unit economics in core markets.

Clover Health Investments (CLOV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLOV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 10, 2026	2026 (Q2)	0.04 / -	-0.02	―	―	―
May 06, 2026	2026 (Q1)	0.07 / 0.07	0.053	37.74% (+0.02)
Feb 26, 2026	2025 (Q4)	-0.10 / -0.05	-0.04	-27.50% (-0.01)
Nov 04, 2025	2025 (Q3)	-0.03 / -0.05	-0.02	-150.00% (-0.03)
Aug 05, 2025	2025 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 06, 2025	2025 (Q1)	-0.04 / 0.05	-0.05	206.00% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.07 / -0.04	-0.146	72.60% (+0.11)
Nov 06, 2024	2024 (Q3)	-0.04 / -0.02	-0.086	76.74% (+0.07)
Aug 05, 2024	2024 (Q2)	-0.05 / 0.01	-0.06	116.67% (+0.07)
May 07, 2024	2024 (Q1)	-0.07 / -0.05	-0.152	67.11% (+0.10)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLOV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2026	$2.68	$2.82	+5.22%
Feb 26, 2026	$2.15	$2.09	-2.79%
Nov 04, 2025	$3.52	$2.96	-15.77%
Aug 05, 2025	$2.85	$2.26	-20.70%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.